Just to be clear, I agree synthetic is the way for to go, which is what Inmed, Zynerba, etc. are also doing. I'm not sure how much of a market share a cannabinoid based antiemetic could capture if it's considered last line, which is why I was curious about vinpat's valuation. Perhaps their buccal patch will change that, when ready.
It will also be interesting to see the efficacy of the current prodrug against a THC suppository. Do you remember seeing a comparison for a previous formulation?
News 
Market Data 
Discover 
